Navigation Links
GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer
Date:12/11/2009

LONDON and PHILADELPHIA, Dec. 11 /PRNewswire/ -- In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

The study included 296 women with a type of breast cancer known as HER2-positive disease, characterized by an overexpression of the HER2 protein in the cancer cells. Patients enrolled in the study experienced recurrence of breast cancer despite a median of three prior trastuzumab-based therapies. The data presented at the San Antonio congress showed that patients overcame resistance to trastuzumab with the introduction of the lapatinib-trastuzumab combination.

"The clinical benefits brought forth by the lapatinib and trastuzumab combination are quite compelling and lead me to believe the agents may be acting together to form a sort of 'dual blockade' to obstruct the HER2 pathway necessary for the tumor to thrive," said primary investigator, Kimberly Blackwell, M.D., Duke University Medical Center.

Patients in the study were randomized to receive single agent lapatinib (1500 mg/daily) or a combination of lapatinib (1000 mg p.o. daily) plus trastuzumab (2 mg/kg). For those patients treated with monotherapy lapatinib, cross-over to the combination was allowed if the disease progressed after at least four weeks of therapy. Final analysis showed clinical activity for lapatinib in the control arm. Women treated with monotherapy lapatinib experienced a median overall survival of 9.5 months compared with 14 months when treated with the combination (median HR: 0.74, p=0.026).

"It's possible that, by lapatinib working inside the c
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
2. Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer
3. DecisionView Launches StudyOptimizer(TM) 4
4. Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
5. OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months
6. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
7. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
8. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
9. Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
10. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
11. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
(Date:7/24/2014)... July 24, 2014  Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the first ... quarter overview: , Revenues of $47.5 million, up ... EPS of $0.21, up 50% over last year,s comparable ... revenues of $7.2 million, up 20% over last year,s ...
(Date:7/24/2014)... 2014 IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has accepted  ... Mr. Finio has accepted a senior level finance position ... his acceptance of his new position, Mr. Finio will ... for IGI Laboratories, Inc.  The effective date of his ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... Feb. 1, 2011 /PRNewswire-Asia-FirstCall/ --  China Medicine Corporation ... "Company"), a leading manufacturer, developer and distributor of ... health products in the People,s Republic of China, ... manufacturing license from the Chinese Ministry of Agriculture ...
... 2011 Stryker Corporation (NYSE: SYK ) ... of its OP-1 product family, which includes OP-1 Implant, ... bone applications. The transaction also includes the sale of ... Stryker is one of the world,s leading medical technology ...
Cached Medicine Technology:China Medicine Corporation Receives Manufacturing License for rADTZ 2China Medicine Corporation Receives Manufacturing License for rADTZ 3
(Date:7/24/2014)... shuts off nighttime production of the hormone melatonin, renders ... breast cancer drug, says a new study by Tulane ... and Melatonin Disruption by Exposure to Light at Night ... published in the journal Cancer Research , is ... the success of tamoxifen in treating breast cancer. , ...
(Date:7/24/2014)... Ticket Down is a reliable source ... at the Sports Authority Field on July 26th. For the ... has brought some of the best club teams from around the ... still being raved about weeks after its completion, fans – new ... of the biggest stars in the world compete. Some of these ...
(Date:7/24/2014)... 2014 Four Seasons Resort Maui ... its $3 million renovation of the famed Maile suite ... suites, just in time to welcome summer guests vacationing ... direction from the internationally-acclaimed BraytonHughes Design Studios, San Francisco ... property and the largest in Hawaii—received a complete re-envisioning. ...
(Date:7/24/2014)... In a July 9th article in the Money ... Lotus Blossom Consulting LLC , was quoted in a Family ... Cut the High Cost of Infertility . Her advice began ... maximize your chance of success from the first attempt.” The ... “I am always happy to talk with the media ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 CarePoint ... specialist in hematology and oncology, Dr. Hitendra Upadhyaya, ... Our system welcomes Dr. Upadhyaya to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2
... on Science, Not IdeologyWASHINGTON, March 23 Today, the ... York ruled that the Food and Drug Administration (FDA) ... dedicated emergency contraceptive product) based on age was "arbitrary ... faith decision-making." The court ordered the FDA to extend ...
... Recommended levels in foods need to be increased, experts ... the course of two decades, vitamin D levels have ... Low levels of vitamin D have been associated with ... adults. Recent research has also linked insufficient vitamin D ...
... seen with tightest control of risk factors, researchers report ... control of the major risk factors for heart disease ... a new study shows. , And so the current ... LDL cholesterol might need to be tightened even further, ...
... a Decision Based on Scientific Fact, Not PoliticsNEW YORK, March ... the Eastern District of New York rejected the Food and ... emergency contraceptive Plan B to women over 18, ruling that ... The court ordered the agency to reconsider its decision. ...
... in Virginia, West Virginia and Maryland to hold annual convention recognizing ... ... 23, 2009 -- 200 emergency and 911 professionals will gather in ... safety sector. The 16th Annual Tri-State Telecommunicators Banquet and Awards ...
... Inform Healthcare DecisionsPHILADELPHIA, March 23 ... when selecting a hospital for treatment, thanks to ... and facility.Synthesizing extensive data from the 2003-2007 ... Hospital Performance Reports (PHC4) into a searchable format, ...
Cached Medicine News:Health News:Advocates for Youth Applauds Court Ruling on EC Age Restriction 2Health News:Many Americans Fall Short on Their Vitamin D 2Health News:Many Americans Fall Short on Their Vitamin D 3Health News:Many Americans Fall Short on Their Vitamin D 4Health News:Lowest Blood Pressure, Cholesterol Levels the Best 2Health News:Lowest Blood Pressure, Cholesterol Levels the Best 3Health News:Federal Court Rules FDA Must Reconsider Plan B Decision 2Health News:Federal Court Rules FDA Must Reconsider Plan B Decision 3Health News:LLE to Sponsor 16th Annual Tri-State Telecommunicators Banquet and Awards Ceremony 2Health News:New Site Compares Pennsylvania Hospitals 2
... mini-cells has always distinguished itself by ... tradition continues with the patented XCell ... gel tension wedge in place of ... models makes the XCell SureLock and ...
... Multidizer is designed with a variety of ... - all in one unit. Shake, rock, ... operating compartments allow for hybridization and blotting ... , The upper chamber uses a ...
... unit ideal for use in laboratories with low ... set at 12 rpm , Temperature control ... capacity of four 35 x 150mm bottles, eight ... , Consistent, repeatable results achieved with microprocessor ...
Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
Medicine Products: